The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,825
Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction
Berridge, M. J., & Irvine, R. F. (1984) · Nature · doi:10.1038/312315a0 · Cited by 6,086
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,135
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martínez, J., & Khrestchatisky, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,523
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Items 101–200 of 429
Revolutionizing peptide‐based drug discovery: Advances in the post‐AlphaFold era
Chang, L., Mondal, A., Singh, B., Martínez‐Noa, Y., & Perez, A. (2024) · WIREs Computational Molecular Science · doi:10.1002/wcms.1693 · Cited by 56
Oxytocin and vasopressin inhibit hyper-aggressive behaviour in socially isolated mice
Tan, O., Musullulu, H., Raymond, J. S., Wilson, B. B., Langguth, M., & Bowen, M. T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.016 · Cited by 59
Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Japundzic-Zigon, N., Lozic, M., Šarenac, O., & Murphy, D. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190717150501 · Cited by 43
Hedges, V. L., Heaton, E. C., Amaral, C., Benedetto, L. E., Bodie, C. L., D’Antonio, B. I., Portillo, D. R. D., Lee, R. H., Levine, M., O’Sullivan, E. C., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.11.016 · Cited by 56
Madrid, J. E., Parker, K. J., & Ophir, A. G. (2020) · Advances in the study of behavior · doi:10.1016/bs.asb.2020.02.001 · Cited by 55
Li, L., Yuan, W., He, Z., Wang, L., Jing, X.-Y., Zhang, J., Yang, Y., Guo, Q., Zhang, X., Cai, W., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.12.238 · Cited by 57
Yamashita, M., Takayanagi, Y., Yoshida, M., Nishimori, K., Kusama, M., & Onaka, T. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12019 · Cited by 54
Selective localization of oxytocin receptors and vasopressin 1a receptors in the human brainstem
Freeman, S. M., Smith, A. L., Goodman, M. M., & Bales, K. L. (2017) · Social Neuroscience · doi:10.1080/17470919.2016.1156570 · Cited by 51
Collins, J. S., Tanaka, J., Wilson, P., Kempe, K., Davis, T. P., McIntosh, M. P., Whittaker, M. R., & Haddleton, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5006202 · Cited by 51
Role of oxytocin in the ventral tegmental area in social reinforcement
Borland, J. M., Grantham, K. N., Aiani, L. M., Frantz, K. J., & Albers, H. E. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.028 · Cited by 62
Martian, P. C., Tertiş, M., Leonte, D., Hădade, N. D., Cristea, C., & Crisan, O. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116488 · Cited by 52
Global map of oxytocin/vasopressin-like neuropeptide signalling in insects
Liutkevičiūtė, Z., Koehbach, J., Eder, T., Gil‐Mansilla, E., & Gruber, C. W. (2016) · Scientific Reports · doi:10.1038/srep39177 · Cited by 49
Exploring bioactive peptides from natural sources for oxytocin and vasopressin drug discovery
Gruber, C. W., Koehbach, J., & Muttenthaler, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.108 · Cited by 49
Rigney, N., Beaumont, R., & Petrulis, A. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104715 · Cited by 49
Song, Z., Larkin, T. E., Malley, M. O., & Albers, H. E. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2016.02.004 · Cited by 47
Septal oxytocin administration impairs peer affiliation via V1a receptors in female meadow voles
Anacker, A. M. J., Christensen, J. D., LaFlamme, E. M., Grunberg, D. M., & Beery, A. K. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.025 · Cited by 44
The neurocircuitry involved in oxytocin modulation of methamphetamine addiction
Baracz, S. J., & Cornish, J. L. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.08.001 · Cited by 46
Maldonado, P. P., Nuno‐Perez, A., Kirchner, J. H., Hammock, E. A. D., Gjorgjieva, J., & Löhmann, C. (2020) · Current Biology · doi:10.1016/j.cub.2020.10.028 · Cited by 46
Acheson, D. T., Feifel, D., Kamenski, M., Mckinney, R., & Risbrough, V. B. (2015) · Depression and Anxiety · doi:10.1002/da.22362 · Cited by 44
Giglio, M. G. D., Muttenthaler, M., Harpsøe, K., Liutkevičiūtė, Z., Keov, P., Eder, T., Rattei, T., Arrowsmith, S., Wray, S., Marek, A., et al. (2017) · Scientific Reports · doi:10.1038/srep41002 · Cited by 47
Moaddab, M., & Dabrowska, J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.039 · Cited by 43
Everett, N. A., McGregor, I. S., Baracz, S. J., & Cornish, J. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.036 · Cited by 44
Koto, A., Motoyama, N., Tahara, H., McGregor, S., Moriyama, M., Okabe, T., Miura, M., & Keller, L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817788116 · Cited by 43
Mustoe, A. C., Harnisch, A. M., Hochfelder, B., Cavanaugh, J., & French, J. A. (2016) · Animal Behaviour · doi:10.1016/j.anbehav.2016.01.025 · Cited by 40
Mull, R. W., Harrington, A., Sanchez, L. A., & Tal-Gan, Y. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180518090705 · Cited by 41
Bous, J., Orcel, H., Floquet, N., Leyrat, C., Lai‐Kee‐Him, J., Gaibelet, G., Ancelin, A., Saint‐Paul, J., Trapani, S., Louet, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5628 · Cited by 45
Self-citationNeuroendocrine underpinning of social recognition in males and females
Aspesi, D., & Choleris, E. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13070 · Cited by 41
Oxytocin excites nucleus accumbens shell neurons in vivo
Moaddab, M., Hyland, B. I., & Brown, C. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.08.013 · Cited by 41
Oxytocin enhances the expression of morphine-induced conditioned place preference in rats
Moaddab, M., Hyland, B. I., & Brown, C. H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.01.003 · Cited by 40
Martinon, D., Lis, P., Roman, A. N., Tornesi, P., Applebey, S. V., Buechner, G., Olivera, V., & Dabrowska, J. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0474-x · Cited by 41
Oxytocin Receptor Signaling in Vascular Function and Stroke
McKay, E. C., & Counts, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.574499 · Cited by 45
Stadler, B., Whittaker, M. R., Exintaris, B., & Middendorff, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.565731 · Cited by 43
Borie, A. M., Dromard, Y., Guillon, G., Olma, A., Manning, M., Muscatelli, F., Desarménien, M. G., & Jeanneteau, F. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144450 · Cited by 41
Self-citationOxytocin and vasopressin signaling in health and disease
Perisic, M., Woolcock, K., Hering, A., Mendel, H. C., & Muttenthaler, M. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.01.010 · Cited by 42
Reviving-like prosocial behavior in response to unconscious or dead conspecifics in rodents
Sun, W., Zhang, G., Huang, J., Tao, C., Seo, M. B., Tao, H. W., & Zhang, L. I. (2025) · Science · doi:10.1126/science.adq2677 · Cited by 40
Harden, S. W., & Frazier, C. J. (2016) · Hippocampus · doi:10.1002/hipo.22595 · Cited by 44
A Three‐Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors
Saleh, N., Saladino, G., Gervasio, F. L., Haensele, E., Banting, L., Whitley, D. C., Santos, J. S. O., Bureau, R., & Clark, T. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201602729 · Cited by 40
Intranasal oxytocin modulates neural functional connectivity during human social interaction
Rilling, J. K., Chen, X., Chen, X., & Haroon, E. (2018) · American Journal of Primatology · doi:10.1002/ajp.22740 · Cited by 40
Wong, J. C., Shapiro, L. E., Thelin, J. T., Heaton, E. C., Zaman, R. U., D’Souza, M. J., Murnane, K. S., & Escayg, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105147 · Cited by 39
Cid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 40
Otero‐García, M., Martín‐Sánchez, A., Fortes-Marco, L., Martínez‐Ricós, J., Agustín‐Pavón, C., Lanuza, E., & Martínez‐Garciá, F. (2013) · Brain Structure and Function · doi:10.1007/s00429-013-0553-3 · Cited by 42
Chen, X., Nishitani, S., Haroon, E., Smith, A. K., & Rilling, J. K. (2019) · Genes Brain & Behavior · doi:10.1111/gbb.12555 · Cited by 39
Dwivedi, N., Tao, S., Jamadar, A., Sinha, S., Howard, C., Wallace, D. P., Fields, T. A., Leask, A., Calvet, J. P., & Rao, R. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020020190 · Cited by 38
Marmosets treated with oxytocin are more socially attractive to their long-term mate
Cavanaugh, J., Huffman, M. C., Harnisch, A. M., & French, J. A. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00251 · Cited by 36
New, Potent, and Selective Peptidic Oxytocin Receptor Agonists
Wiśniewski, K., Alagarsamy, S., Galyean, R., Tariga, H., Thompson, D., Ly, B., Wiśniewska, H., Qi, S., Croston, G. E., Laporte, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500365s · Cited by 37
Suraev, A. S., Bowen, M. T., Ali, S. O., Hicks, C., Ramos, L., & McGregor, I. S. (2014) · Hormones and Behavior · doi:10.1016/j.yhbeh.2014.03.002 · Cited by 35
Cardoso, C., Orlando, M. A., Brown, C. A., & Ellenbogen, M. A. (2014) · Social Neuroscience · doi:10.1080/17470919.2013.873079 · Cited by 38
Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1Areceptors
Taveau, C., Chollet, C., Bichet, D. G., Velho, G., Guillon, G., Corbani, M., Roussel, R., Bankir, L., Melander, O., & Bouby, N. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00269.2016 · Cited by 38
Self-citationWarfvinge, K., Krause, D. N., Maddahi, A., Grell, A.-S., Edvinsson, J. C. A., Haanes, K. A., & Edvinsson, L. I. (2020) · Cephalalgia · doi:10.1177/0333102420929027 · Cited by 36
Garona, J., Pífano, M., Orlando, U. D., Pastrián, M. B., Iannucci, N. B., Ortega, H. H., Podesta, E. J., Gomez, D. E., Ripoll, G. V., & Alonso, D. F. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2952 · Cited by 36
Taylor, J. H., Walton, J. C., McCann, K. E., Norvelle, A., Liu, Q., Vander Velden, J. W., Borland, J. M., Hart, M., Jin, C., Huhman, K. L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121037119 · Cited by 35
Effect of oxytocin receptor blockade on appetite for sugar is modified by social context
Olszewski, P. K., Allen, K. L., & Levine, A. S. (2014) · Appetite · doi:10.1016/j.appet.2014.10.007 · Cited by 35
Interplay between the oxytocin and opioid systems in regulating social behaviour
Putnam, P. T., & Chang, S. W. C. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0050 · Cited by 33
Dumais, K. M., Kulkarni, P. P., Ferris, C. F., & Veenema, A. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.04.003 · Cited by 34
Pífano, M., Garona, J., Capobianco, C. S., González, N., Alonso, D. F., & Ripoll, G. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00011 · Cited by 34
Oxytocin and vasopressin signalling and myometrial contraction
Arrowsmith, S. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2019.10.006 · Cited by 33
Oxytocin: A citation network analysis of 10 000 papers
Leng, G., & Leng, R. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13014 · Cited by 34
Cragg, B., Ji, G., & Neugebauer, V. (2016) · Molecular Pain · doi:10.1177/1744806916676491 · Cited by 33
Molecular basis of pharmacological therapy in Cushing’s disease
Ferone, D., Pivonello, C., Vitale, G., Zatelli, M. C., Colao, A., & Pivonello, R. (2013) · Endocrine · doi:10.1007/s12020-013-0098-5 · Cited by 32
Snider, B. M., Geiser, A., Yu, X.-P., Beebe, E., Willency, J. A., Qing, K., Guo, L., Lu, J., Wang, X., Yang, Q., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00004 · Cited by 32
The Role of Oxytocin in Abnormal Brain Development: Effect on Glial Cells and Neuroinflammation
Knoop, M. S., Possovre, M.-L., Jacquens, A., Charlet, A., Baud, O., & Darbon, P. (2022) · Cells · doi:10.3390/cells11233899 · Cited by 35
Miller, S. L., Serpell, J. A., Dalton, K. R., Waite, K. B., Morris, D. O., Redding, L. E., Dreschel, N. A., & Davis, M. F. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.844252 · Cited by 45
Oxytocin Facilitates Allomaternal Behavior under Stress in Laboratory Mice
Tsuneoka, Y., Yoshihara, C., Ohnishi, R., Yoshida, S., Miyazawa, E., Yamada, M., Horiguchi, K., Young, W. S., Nishimori, K., Kato, T., et al. (2022) · eNeuro · doi:10.1523/eneuro.0405-21.2022 · Cited by 31
Corbani, M., Marir, R., Trueba, M., Chafaï, M., Vincent, A., Borie, A. M., Desarménien, M. G., Ueta, Y., Corbani, M., Olma, A., et al. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.10.011 · Cited by 33
Self-citationDesign and applications of cyclic peptides
Claro, B., Bastos, M., & García‐Fandiño, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100736-5.00004-1 · Cited by 30
Bridging the gap between rodents and humans: The role of non‐human primates in oxytocin research
Putnam, P. T., Young, L. J., & Gothard, K. M. (2018) · American Journal of Primatology · doi:10.1002/ajp.22756 · Cited by 28
“Early attempts to localize OXTRs in NHPs were inconclusive (Toloczko, Young, & Insel, 1997) due to the cross-reactivity of the OT radioligand used for OXTR autoradiography and structurally similar arginine vasopressin receptor (AVPR1A) (Manning et al., 2012).”
BackgroundLozić, M., Greenwood, M. P., Šarenac, O., Martin, A., Hindmarch, C. C. T., Tasić, T., Paton, J. F. R., Murphy, D., & Japundžić‐Žigon, N. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12776 · Cited by 29
Early life manipulations of vasopressin-family peptides alter vocal learning
Baran, N. M., Carouso-Peck, S., Kim, T. H., Goldstein, M. H., & Adkins–Regan, E. (2017) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2017.1114 · Cited by 30
Wiśniewski, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9504-2_11 · Cited by 30
Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges
Che, X., Cai, J., Liu, Y., Xu, T., Yang, J., & Wu, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107820 · Cited by 28
Jamieson, B. B., Bouwer, G. T., Campbell, R. E., & Piet, R. (2021) · Endocrinology · doi:10.1210/endocr/bqab071 · Cited by 28
Baran, N. M., Sklar, N. C., & Adkins–Regan, E. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.10.005 · Cited by 29
Ahern, T. H., Olsen, S., Tudino, R., & Beery, A. K. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105209 · Cited by 27
Novel enabling strategies for oral peptide delivery
Öngoren, B., Kara, A., Serrano, D. R., & Lalatsa, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125888 · Cited by 28
Jacobsen, J. P. R., Plenge, P., Sachs, B. D., Pehrson, A. L., Cajina, M., Du, Y., Roberts, W. L., Rudder, M. L., Dalvi, P. H., Robinson, T. J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3595-1 · Cited by 27
Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., & McGregor, I. S. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.10.002 · Cited by 25
Rigney, N., Campos‐Lira, E., Kirchner, M. K., Wei, W., Belkasim, S., Beaumont, R., Singh, S. P., Suarez, S. G., Hartswick, D., Stern, J. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319641121 · Cited by 26
Griffiths, P. R., Lolait, S. J., Harris, L. E., Paton, J. F. R., & O’Carroll, A. (2017) · The Journal of Physiology · doi:10.1113/jp274178 · Cited by 25
Nonapeptides mediate trade-offs in parental care strategy
DeAngelis, R., Dodd, L., & Rhodes, J. S. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104717 · Cited by 24
Arakawa, H. (2021) · Current Research in Neurobiology · doi:10.1016/j.crneur.2021.100011 · Cited by 26
Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors
Carr, J. C., Sherman, S. K., Wang, D., Dahdaleh, F. S., Bellizzi, A. M., O'Dorisio, M. S., O’Dorisio, T. M., & Howe, J. R. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3318-6 · Cited by 25
Oxytocin structure and function in New World monkeys: from pharmacology to behavior
Mustoe, A. C., Taylor, J. H., & French, J. A. (2018) · Integrative Zoology · doi:10.1111/1749-4877.12318 · Cited by 26
Pitra, S., Zhang, M., Cauley, E. S., & Stern, J. E. (2019) · The Journal of Physiology · doi:10.1113/jp277167 · Cited by 25
Strauss, G. P., Granholm, E. L., Holden, J. L., Ruiz, I., Gold, J. M., Kelly, D. L., & Buchanan, R. W. (2018) · Psychological Medicine · doi:10.1017/s0033291718002465 · Cited by 25
Hirota, Y., Arai, A., Young, L. J., Osako, Y., Yuri, K., & Mitsui, S. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104685 · Cited by 25
Olszewski, P. K., Ulrich, C., Ling, N., Allen, K. L., & Levine, A. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.007 · Cited by 24
Hicks, C., Ramos, L., Reekie, T. A., Narlawar, R., Kassiou, M., & McGregor, I. S. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3902-5 · Cited by 23
Tsushima, H., Zhang, Y., Muratsubaki, T., Kanazawa, M., & Fukudo, S. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.04.011 · Cited by 22
A new hypothesis linking oxytocin to menstrual migraine
Bharadwaj, V. N., Porreca, F., Cowan, R. P., Kori, S. H., Silberstein, S. D., & Yeomans, D. C. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14152 · Cited by 23
Prato, L. C. D., Zayan, U., Abdallah, D., Point, V., Schaller, F., Pallesi‐Pocachard, E., Montheil, A., Canaan, S., Gaïarsa, J., Muscatelli, F., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01313-5 · Cited by 23
Oxytocin excites BNST interneurons and inhibits BNST output neurons to the central amygdala
Francesconi, W., Berton, F., Olivera-Pasilio, V., & Dabrowska, J. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108601 · Cited by 22
Charles, R., Sakurai, T., Takahashi, N., Elder, G. A., Sosa, M. A. G., Young, L. J., & Buxbaum, J. D. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.017053 · Cited by 25
Phospholipase C-β1 and schizophrenia-related behaviors
Koh, H.-Y. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.08.002 · Cited by 21
González-Iglesias, A. E., Fletcher, P. A., Arias-Cristancho, J. A., Cristancho-Gordo, R., Helena, C. V. V., Bertram, R., & Tabak, J. (2014) · Endocrinology · doi:10.1210/en.2014-1543 · Cited by 21
Zhang, L., & Eiden, L. E. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2958-z · Cited by 21
Lema, S. C., Washburn, E. H., Crowley, M. E., Carvalho, P. G., Egelston, J. N., & McCormick, S. D. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00328.2018 · Cited by 21
Erdélyi, L. S., Balla, A., Patócs, A., Tóth, M., Várnai, P., & Hunyady, L. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1424 · Cited by 21
Wsół, A., Szczepanska‐Sadowska, E. K., Kowalewski, S., Puchalska, L., & Cudnoch‐Jędrzejewska, A. (2013) · Stress · doi:10.3109/10253890.2013.872620 · Cited by 21
Barengolts, E. I. (2016) · Endocrine Practice · doi:10.4158/ep151192.ra · Cited by 20
Lemel, L., Nieścierowicz, K., García-Fernández, M. D., Darré, L., Durroux, T., Busnelli, M., Pezet, M., Rébeillé, F., Jouhet, J., Mouillac, B., et al. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100059 · Cited by 19
Self-citation
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
